Macrocure, a late-stage Israeli biotech developing white blood cell injections to treat hard-to-heal wounds, filed on Monday with the SEC to raise up to $75 million in an initial public offering. The Petach Tikva, Israel-based company, which was founded in 2008, plans to list on the NASDAQ under the symbol MCUR. Macrocure initially filed confidentially on May 5, 2014. Credit Suisse and Jefferies are the joint bookrunners on the deal. No pricing terms were disclosed.
